-
7 new domestically produced Class 1 anti-ED drugs are coming, and Yangtze River sprints for the first time!
Time of Update: 2021-04-21
Tadalafil The competition is fierce, and Haisco's avanafil tablets are expected to become the fourth approved anti-ED oral PDE-5 inhibitor in China.
-
"K drug" hit the first shot, bringing new changes to the treatment pattern of esophageal cancer
Time of Update: 2021-04-21
(MSD) announced that the US Food and Drug Administration (FDA) has approved its anti-PD-1 inhibitor Keytruda combined with fluorouracil (FU) and cisplatin for locally advanced or metastatic esophageal cancer Or the first-line treatment of gastroesophageal junction (GEJ) adenocarcinoma.
-
FDA Approves Pembrolizumab for First-line Indications for Esophageal Cancer; China's First RET Inhibitor Pratinib Approved|Tumor News
Time of Update: 2021-04-21
/>The primary endpoint of the study is the objective response rate (ORR), and the secondary endpoints include safety and tolerability. Subjects took Tipifarnib 600 or 900 mg orally twice daily
-
"Ketoconazole + Octreotide", "Osilodrostat"... Will these become new methods of Cushing's treatment?
Time of Update: 2021-04-21
5. Conclusion This prospective study for CS patients confirmed that at the 12th week, metyrapone can effectively reduce UFC levels, tolerability is similar to previously reported safety, and improves the quality of life.
-
"Li" creates extraordinary, "Da" has a promising future│Taboshu® is launched in the new indication
Time of Update: 2021-04-21
In February 2021, Sintilimab was approved by the National Medical Products Administration (NMPA), and its indication is combined with pemetrexed and platinum-based chemotherapy for non-squamous NSCLC without EGFR sensitive mutations or ALK gene rearrangement First-line treatment.
-
Most people infected with the new coronavirus in Wuhan are asymptomatic. Can antibody levels prevent secondary infections?
Time of Update: 2021-04-21
Based on this result, the overall infection rate of the new coronavirus among residents in Wuhan at that time was 6.
-
[Science Sub-Journal] New breakthroughs in cell recombination programming | Cell therapy can help
Time of Update: 2021-04-21
, and repair Damaged brain tissue. The research was published in the journal "Science Advances", entitled "Nanotransfection-based vasculogenic cell reprogramming drives functional recovery in a mouse model
-
Questioned that the data is out of date, AstraZeneca announces the clinical data of the new crown vaccine
Time of Update: 2021-04-21
for people who want to It is undoubtedly great news for AstraZeneca, which has entered the United States. Surprisingly, shortly after this data was released, it was questioned by the National Institute of Allergy
-
Daily review of epichlorohydrin: a new low
Time of Update: 2021-04-21
The prices of downstream epoxy resins have continued to fall and affected raw materials; the spot market continued to fall sharply during the week.
-
Daily review of BPA: external bad news
Time of Update: 2021-04-20
On the trading day (August 09, 2011), the bisphenol A raw material market showed empty profits (omitted, see the full version for details).
-
PAWNN score predicts hospital death risk of new crown patients
Time of Update: 2021-04-20
Click [Medical side] Follow us today to share with you a new paper published by researchers from Wuhan University in Med magazine, a subsidiary of Cell on January 7, 2021. The author uses machine
-
Comparison of breeding stocks of sows: New Hope has the largest increase, Muyuan shares
Time of Update: 2021-04-20
23 million sowsYd4 China Feed Industry Information Network-Based on feed, serving animal husbandry On March 1, Zhengbang Technology disclosed on the Shenzhen Stock Exchange Interactive: As of the end of January, the company was able to breed 1.
-
Sub-Journal of "Cell": The new coronavirus can evade antibodies in the nose!
Time of Update: 2021-04-20
>They found that after vaccination, lung infections and damage were indeed significantly reduced, but infections in the nasal cavity did not decrease. Researchers believe that this will have a significant impact on reinfection and vaccines.
-
AstraZeneca announces Phase 3 data for new crown vaccine
Time of Update: 2021-04-20
On March 25, local time, AstraZeneca's official website announced that the preliminary analysis results of the phase III clinical trial of the new crown vaccine AZD1222 were consistent with the interim analysis results announced on March 22.
-
The ideal disease-modifying drug for multiple sclerosis under the new crown epidemic, have you chosen the right one?
Time of Update: 2021-04-20
Among the DMT drugs that can be used safely under the epidemic situation recommended by the guidelines, teriflunomide does not cause severe immunosuppression, does not increase the risk of infection, and does not affect the effectiveness of inactivated vaccination.
-
BPA daily review: bad news is still there
Time of Update: 2021-04-20
On the last trading day (June 03, 2011), the mainstream transaction price in the East China region of the mainstream market continued to maintain the range of 18,700 to 19,100 yuan/ton.
-
Treat To Target, a picture to understand the "new" concept of the treatment of reflux esophagitis!
Time of Update: 2021-04-20
Previous recommendations: Two or three things about the nighttime symptoms of reflux esophagitis, one picture to understand!
Obesity is actually related to reflux esophagitis!
-
Nat Hum Behav: New research links genes to the function of the human brain
Time of Update: 2021-04-20
This separation can be traced back to gene expression in specific cell types and molecular pathways, providing key insights for future research on mental illness.
-
Nat Comm | Huang Haojie's team reveals a new mechanism of resistance in prostate cancer
Time of Update: 2021-04-20
effects on second-generation androgen receptor inhibitors (such as ENZ), and most patients quickly develop resistance. Therefore, exploring the resistance mechanism of CRPC to enzalutamide and finding new
-
New natural enemy of tumor?
Time of Update: 2021-04-20
Ott and his colleague Eryn Blass from the Dana Farber Cancer Institute in Boston, USA published an article entitled "Advances in the development of personalized neoantigen-based therapeutic" in Nature Reviews-Clinical Oncology.
